Aflac AFL Cancer — Interest Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aflac in its filing.
Tagged under the XBRL concept us-gaap:LiabilityForFuturePolicyBenefitInterestExpense.
The official record: Aflac’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aflac's cancer — interest expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aflac's cancer — interest expense?
- Aflac (AFL) reported cancer — interest expense of $217M in Q1 2026.
- How has Aflac's cancer — interest expense changed year-over-year?
- Aflac's cancer — interest expense decreased by 6.9% year-over-year, from $233M to $217M.
- What is the long-term trend for Aflac's cancer — interest expense?
- Over 4 years (2021 to 2025), Aflac's cancer — interest expense has grown at a -10.0% compound annual growth rate (CAGR), from $1.43B to $935M.
- What does cancer — interest expense mean?
- This represents the interest costs associated with the liabilities held for the cancer insurance segment. It reflects the cost of financing the reserves required to meet future policy obligations. Managing this expense is crucial for maintaining the profitability of the insurance product line.